ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Qilu Pharmaceutical Co., Ltd. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 218 studies whose lead sponsor is Qilu Pharmaceutical Co., Ltd. or one of 3 companies grouped under it. 135 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 4 registry names, not the registry’s. See them and correct one ↓

Compare Qilu Pharmaceutical with Johnson & Johnson and Merck →

Pipeline: 71 programs

Each counted once: 71 with a study Qilu Pharmaceutical Co., Ltd. leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 of 32 with the most live studies.

Program
Iparomlimab/TuvonralimabPhase 3 · 14 live · Uterine Cervical Neoplasms · primary completion Jun 2027☆ Track
QLC5508Phase 3 · 6 live · Small Cell Lung Carcinoma · primary completion Dec 2026☆ Track
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905Phase 3 · 5 live · Pancreatic Neoplasms · primary completion Dec 2026☆ Track
QL2107Phase 3 · 5 live · Carcinoma, Non-Small-Cell Lung · primary completion Dec 2026☆ Track
QLC7401Phase 3 · 5 live · Hyperlipoproteinemia Type II · primary completion Oct 2027☆ Track

27 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Qilu Pharmaceutical Co., Ltd.’s own registered studies; Qilu Pharmaceutical Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Qilu Pharmaceutical Co., Ltd.’s studies test, most open studies first — 62 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 62; every drug is on its own page, and each page lists its sponsors.

Coming up

49 of Qilu Pharmaceutical Co., Ltd.’s studies under way reach primary completion within a year, 19 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 2N’26
  2. 10D
  3. 2J’27
  4. 1F
  5. 2M
  6. 6A
  7. 6M
  8. 8J
  9. 1J
  10. 2A
  11. 2S
  12. 3O
  13. 4N

The 12 nearest

Show 7 more

Add all 49 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 19, 2026.

All 218 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now13562%Not yet recruiting 81 · Recruiting 53 · Enrolling by invitation 1
  • Under way, not recruiting84%
  • Completed3215%
  • Stopped early1<1%
  • Status unknown or other4219%

Phase

Where

  • China146
  • United States2
  • Romania1
  • Bosnia and Herzegovina1
  • Hungary1
  • India1

Over the years

  1. 13
  2. 14
  3. 15
  4. 16
  5. 17
  6. 18
  7. 19
  8. 20
  9. 21
  10. 22
  11. 23
  12. 24
  13. 25
  14. 5226

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Qilu Pharmaceutical Co., Ltd.

  • Qilu Pharmaceutical Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    200 studies
  • Qilu Pharmaceutical (Hainan) Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    8 studies →
  • Shanghai Qilu Pharmaceutical Research and Development Center LTD
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    8 studies →
  • Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →

Focus areas

Conditions Qilu Pharmaceutical Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 218. Browse all 218 →